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Title:
Rheumatoid leptomeningitis presenting with an acute neuropsychiatric disorder

Abstract:
Leptomeningitis is a rare central nervous system manifestation of rheumatoid arthritis
(RA), generally in patients with established chronic rheumatoid disease. We report a
41-year-old man without previous RA or psychiatric disorder presenting with an acute
neuropsychiatric disturbance and polyarthralgia.
MRI brain showed asymmetric bi-frontal leptomeningitis, confirmed on (18F)-fluoroD-glucose-positron emission tomography. Other investigations revealed highly
positive serum and CSF anti-cyclic citrullinated peptide. A leptomeningeal biopsy
showed necrotising leptomeningeal inflammation with ill-defined granulomas and
lymphoplasmacytic infiltrate without organisms. Prolonged high-dose corticosteroids
and then rituximab resulted in recovery.
Chronic leptomeningitis can present with an acute neuropsychiatric disorder. We
highlight that early rheumatoid disease can, rarely, cause a chronic leptomeningitis,
reversible with immunotherapy.

Key words:
Rheumatoid Meningitis; Leptomeningitis; Pachymeningits; Neuropsychiatric
disturbance; Rheumatoid Arthritis

Introduction:
Leptomeningitis is a rare manifestation of central nervous system involvement in
rheumatoid arthritis (RA), usually presenting with focal neurological signs in patients
with established disease. We report a patient with only a short history of
polyarthralgia, who presented with an acute neuropsychiatric disturbance, and a
chronic fronto-temporal leptomeningitis, which turned out on serology and biopsy to
reflect rheumatoid disease. He was successfully treated with corticosteroids and
rituximab. Four months later, he began a graded return to work.

Clinical Summary:
A previously well 41-year-old man of Nicaraguan origin was brought to the
Emergency Department by co-workers, concerned about a four-day deterioration in
mental state. His psychiatric symptoms included elevated and irritable mood;
increased energy and reduced sleep; out of character risk-taking; grandiose and
persecutory delusions; and plans to spend large sums of money on a sports car and
property development. This was preceded by several months of reduced frustration
tolerance, as reported by his wife. He complained only of chronic headache and
migratory palindromic, large and small joint polyarthritis for 18-months, self-treated
with indomethacin for a few weeks due to suspected gout. He was a non-smoker with
a social alcohol consumption and denied recreational drug use. Much later it emerged
that three-months before this he had seen a private neurologist about transient sensory
symptoms and leg weakness. MRI brain showed early leptomeningeal changes,
however he did not reveal this to his family and failed to attend his scheduled followup consultations, in hindsight likely due to early executive dysfunction.

On examination he was afebrile, without focal neurological signs, normal fundi and a
supple neck. He was agitated, disinhibited and irritable, with pressured speech, mild
thought disorder, persecutory and grandiose delusions. He could not recall recent
events and was disorientated in time. His right elbow was swollen and painful. There
were no nodules, rashes, nail changes or lymphadenopathy. All tests for drug-induced,
infective or toxic/metabolic causes were negative (Supplementary Table 1). Brain

MRI showed leptomeningeal enhancement over both hemispheres especially the right
frontal lobe (Figure 1:A,B) confirmed on neurological FDG-PET/CT with markedly
increased glucose metabolism over the right frontal and temporal cortices (SUV 20.4
compared to 13.3 on the left), Figure 1:E,F). Neuropsychological evaluation
confirmed behavioural and executive dysfunction with impaired mental flexibility,
disinhibition, impulsivity and perseveration. Language, attention, visuospatial skills
and memory remained preserved. Whole body PET/CT showed increased uptake in
the right elbow (SUV 10.4, left elbow 2.1) consistent with inflammation, with
moderately avid lymph nodes in the right axilla and supraclavicular fossa (Figure
1:G). EEG showed no focal slowing or epileptiform features. Examination of fresh
CSF showed only one mononuclear cell, no organisms, protein 0.39g/L (N=0.150.45), glucose 3.4 mmol/L (N=2-4), normal cytology and flow cytometry. Ultrasound
of the right elbow confirmed synovitis. A right supraclavicular lymph node biopsy
showed only reactive changes, no granulomas; acid-fast smears, tuberculosis (TB)
polymerase chain reaction (PCR) and mycobacterial cultures were negative. Serum
anti-cyclic citrullinated peptide (CCP) antibody was >600U/mL (N<10); CSF antiCCP was strongly positive. Rheumatoid factor was 8 IU/mL (N<15) and a vasculitic
screen was unremarkable. Interferon-gamma release assay (IGRA) was positive
suggesting TB, latent or active. A biopsy of the leptomeninges and the right frontal
cortex showed necrotising inflammation with ill-defined granulomas and a dense
lymphoplasmacytic infiltrate involving the leptomeninges (Figure 2:A,B,C). The
underlying cortex showed rare superficial vessels with mild perivascular lymphocytic
inflammation but was otherwise uninvolved. There was no evidence of vasculitis. No
acid-fast bacilli, fungi or treponemes were identified on special stains. Tissue flowcytometry showed a polyclonal plasma cell population with no evidence of a
lymphoproliferative disorder. Immunohistochemistry showed no evidence of IgG4related disease. TB-PCR and mycobacterial cultures were negative, even after threemonths. The histological diagnosis favoured rheumatoid meningitis.

Treatment included three-day pulse 1g IV methylprednisolone with a high-dose oral
prednisolone taper over six-months, with empirical cover for possible active TB with
rifampicin, isoniazid, pyrazinamide and ethambutol. Two-doses of 1g IV rituximab,
one-month after initiating steroids resulted in sustained improvement of
neuropsychiatric and joint symptoms. B-cell monitoring showed adequate depletion

post rituximab. Oral olanzapine and diazepam, both 10mg twice daily assisted in the
management of psychotic symptoms and behavioural disturbance in the setting of an
acute neurological ward. Initial management also required the use of the relevant local
mental health legislation with one-to-one nursing to reduce the risk that he would
abscond. Capacity to make medical decisions was monitored and substitute decisionmaking was not required. After two-months he was discharged home with resolution
of manic and psychotic symptoms, headache and synovitis but with persisting
executive dysfunction. He continued on 60mg prednisolone daily and a weaning dose
of olanzapine. A progress MR scan at three-months (Figure 1:C,D) showed marked
reduction in leptomeningeal enhancement and thickening. Progress
neuropsychological evaluation at four-months showed resolution of impulsive and
disinhibited behaviour although he continued to show reduced mental flexibility. He
began a graded return to work at that time but not yet to his previous level of authority
and responsibility.

Discussion:

This patient’s acute neuropsychiatric disturbance was due to frontal lobe cortical
inflammation secondary to leptomeningitis. Lack of prior mental health history,
normal metabolic/toxicology investigations, unremarkable CSF and asymmetric
bifrontal leptomeningeal enhancement on MRI indicated an inflammatory or
infiltrative leptomeningitis/pachymenigitis. Lymphoma, IgG4–related disease, TB,
granulomatosis with polyangiitis, neurosarcoidosis, neurosyphilis and meningeal
metastases were all considered (1), but migratory inflammatory arthritis and headache
favoured rheumatoid meningitis and was supported by serum and CSF anti-CCP as
well as the meningeal histology. The leptomeningeal granulomas were distinct from
sarcoid which are typically well formed, not necrotic and do not have a large
lymphoplasmacytic inflammatory component. As the IGRA suggested TB exposure,
TB meningitis was considered although TB-PCR and repeat CSF analysis could not
identify active meningeal TB and mycobacterial cultures were negative after theremonths. After two-months of initial TB treatment, he continued on three-times weekly
rifampicin and isoniazid to complete twelve-months treatment. The improvement in
neuropsychiatric and joint symptoms and MRI reflected intensified treatment with
rituximab coupled with a sustained slow taper of steroids, rather than TB treatment.

Rheumatoid meningitis more often involves the pachymeninges rather than the
leptomeninges and appears granulomatous, occasionally with rheumatoid nodules and
features of vasculitis. A confident diagnosis can only be made from tissue biopsy (2).
There is inflammation with fibrinoid necrosis surrounded by lymphocytes and
epithelioid histiocytes, with variable plasma cell infiltrate (1). Recent reviews of 29
(1) and 48 (2) rheumatoid meningitis patients suggest focal neurological changes,
hemiparesis or hemi-sensory changes mimicking stroke or focal epilepsy are the usual
presenting features (3), with about 2/3 of cases demonstrating asymmetric meningeal
involvement on MRI (1). Most rheumatoid meningitis patients were known to have
RA long before they developed leptomeningitis; ten reports suggest a
neuropsychiatric disturbance, coinciding with seizures, myoclonus or hemiparesis (2).
Only six reports document neurological manifestations without prior RA, with joint
symptoms occurring with or soon after the onset of rheumatoid meningitis (2, 4-6).

Consensus about the treatment of rheumatoid meningitis is lacking. Corticosteroids
and other disease-modifying immunosuppressive agents have been reported, including
methotrexate, cyclophosphamide (2, 7), as well as tumour necrosis factor-alpha
antagonists (8). This is the third reported case of rheumatoid meningitis successfully
treated with rituximab (8, 9). The treatment was complicated by evidence of previous
TB exposure. However, lack of systemic involvement, normal CSF parameters and
strongly positive serum and CSF anti-CCP favoured rheumatoid meningitis over TB
meningitis. We found no previous reports of rheumatoid meningitis presenting as an
isolated acute neuropsychiatric disturbance, responsive to immunotherapy.

This case illustrates that rheumatoid disease needs to be considered in patients
presenting with leptomeningitis, even in those without established RA. Clinical
evaluation of joint symptoms and signs, anti-CCP (as well as rheumatoid factor) and
then meningeal biopsy will confirm the diagnosis. The clinical features of this case
crossed numerous disciplines, highlighting the importance of cooperation and
collaboration between specialties.

Conflicts of Interest and Disclosures:
All authors declare no disclosures.

Highlights:


Rheumatoid disease is a rare cause of leptomeningitis and can occur before a
diagnosis of rheumatoid arthritis is made.



Rheumatoid leptomeningitis can rarely present as an acute neuropsychiatric
disorder.



Rheumatological history, examination and a meningeal biopsy need to be
considered in the investigation of patients with leptomeningitis.



Intensive immunotherapy can reverse the leptomeningitis and associated
neurological features.

Figure Legends:

Figure 1:
MR scan: A) coronal enhanced image shows asymmetric leptomeningeal thickening
and enhancement over both frontal lobes; B) sagittal enhanced image shows
leptomeningeal enhancement over right hemisphere. Progress three month MR scan
C) coronal and D) sagittal enhanced images showing reduction in leptomeningeal
enhancement and thickening.
FDG PET-CT scans: E) transaxial image shows markedly increased metabolism
overlying right infero-mid frontal lobe; F) sagittal image shows extensive right frontal
metabolism; G) whole body projection image shows markedly increased uptake in the
right elbow (SUV 10.4l) consistent with inflammation. Also moderately increased
glucose avid lymph nodes in the right axilla and supraclavicular fossa.

Figure 2:
A) Dense leptomeningeal inflammation and mild superficial cortical perivascular
lymphocytosis (magnification 4x). B) Occasional necrotising granulomas with
neutrophils (magnification 40x). C) Numerous multinucleated giant cells and dense
lymphoplasmacytic inflammation (magnification 40x).

Supplementary Table 1:
Investigation Results
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